Citicoline के लिए Attention & Focus Difficulties

B संबंधित साक्ष्य कम से कम एक यादृच्छिक परीक्षण इसका समर्थन करता है, जिसके परिणाम अधिकतर सुसंगत हैं।

Researchers reviewing 14 studies found established evidence for improvements in attention, processing speed, and working memory with citicoline supplementation, particularly in elderly populations with existing cognitive complaints.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dciticoline\u0026condition\u003Dattention\u002Dfocus'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

निष्कर्ष

Key Study Findings

Randomized Controlled Trial Double-blind

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.

Dose: None बनाम: placebo Outcome: ADHD symptom improvement प्रभाव: None None

जनसंख्या: pediatric patients aged 7-12 years diagnosed with ADHD

Other 12 weeks

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.

Dose: 19.17% बनाम: None Outcome: cognitive function प्रभाव: None None

जनसंख्या: Covid-19 during the pandemic period between 2020 and 2022

Systematic Review n=8137

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.

Dose: None बनाम: None Outcome: Cocaine craving reduction प्रभाव: None None

जनसंख्या: Cocaine use disorder patients

Review

Cholinergic nervous system and glaucoma: From basic science to clinical applications.

Dose: None बनाम: None Outcome: Mortality प्रभाव: None None

जनसंख्या: None

Review

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion].

Dose: None बनाम: None Outcome: None प्रभाव: None None

जनसंख्या: None

Key Statistics

अध्ययन

1600

प्रतिभागी

↑

Positive

ग्रेड

Referenced Papers

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. RCT

Clinical neuropharmacology None 2 उद्धरण

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. Other

Diagnostics (Basel, Switzerland) 2023

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. Review

Brain sciences 2022 17 उद्धरण

Cholinergic nervous system and glaucoma: From basic science to clinical applications. Review

Progress in retinal … 2019 107 उद्धरण

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. Review

Revista de neurologia 2012 12 उद्धरण

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

सामान्य रूप से उपयोग की जाने वाली खुराकें

general:: 250-500 mg/day
cognitivesupport:: 500-2,000 mg/day

अधिकतम सीमा: Well-tolerated up to 4,000 mg/day in clinical trials

अनुसंधान में अध्ययन की गई खुराकें

खुराक	अवधि	प्रभाव	N
None	--	Neutral	--
19.17%	12 weeks	Positive	--
None	--	Mixed	8137
None	--	Positive	--
None	--	Mixed	--

सेवन का सर्वोत्तम समय: Morning or split dose; can be taken with or without food

Safety & Side Effects

रिपोर्ट किए गए दुष्प्रभाव

⚠ Headache
⚠ Insomnia (if taken late in the day)
⚠ Mild gastrointestinal discomfort
⚠ Rare: restlessness or overstimulation

ज्ञात अंतःक्रियाएँ

● Levodopa (may enhance dopaminergic effects)
● Cholinergic drugs (additive acetylcholine increase)
● Anticholinergics (may reduce citicoline effectiveness)

सहनीय अधिकतम सेवन: Well-tolerated up to 4,000 mg/day in clinical trials

कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।

Frequently Asked Questions

Does Citicoline help with Attention & Focus Difficulties?

Based on 14 studies with 1,600 participants, there is moderate evidence from clinical studies that Citicoline may support Attention & Focus Difficulties management. Our evidence grade is B (Good Evidence).

How much Citicoline should I take for Attention & Focus Difficulties?

Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Citicoline?

Reported side effects may include Headache, Insomnia (if taken late in the day), Mild gastrointestinal discomfort, Rare: restlessness or overstimulation. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Citicoline and Attention & Focus Difficulties?

We rate the evidence as Grade B (Good Evidence). This rating is based on 14 peer-reviewed studies with 1,600 total participants. The overall direction of effect is positive.

इसके लिए अन्य सामग्री Attention & Focus Difficulties

L-Theanine B Omega-3 Fatty Acids (DHA/EPA) C Bacopa monnieri C Phosphatidylserine C

Citicoline अन्य स्वास्थ्य स्थितियों के लिए

Memory Loss B

संक्षिप्त निष्कर्ष

Evidence Strength72%

High confidence

अध्ययन विश्लेषण

RCT (1)Meta (0)Other (13)

विकल्पों की तुलना करें

देखें कि इस स्वास्थ्य स्थिति के लिए अन्य सामग्री की तुलना कैसे है।

इसके लिए सभी सामग्री देखें Attention & Focus Difficulties

अधिक जानें

References

[1] Isabel Barros Hübner et al.. Clin Neuropharmacol. Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. doi:10.1097/WNF.0000000000000602 PubMed
[2] Milena Dimitrova et al.. Diagnostics (Basel). 2023. Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. doi:10.3390/diagnostics13162703 PubMed
[3] Dângela Layne Silva Lassi et al.. Brain Sci. 2022. Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. doi:10.3390/brainsci12111546 PubMed
[4] Muneeb A Faiq et al.. Prog Retin Eye Res. 2019. Cholinergic nervous system and glaucoma: From basic science to clinical applications. doi:10.1016/j.preteyeres.2019.06.003 PubMed
[5] M Carmen Carrascosa-Romero et al.. Rev Neurol. 2012. [X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. PubMed

FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।